Vaxart, Inc. Announces New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
May 03, 2021 at 03:06 pm EDT
Share
Vaxart, Inc. announced at Vaxart’s key opinion leader event that new data obtained from its Phase I COVID-19 trial added to the evidence suggesting that VXA-CoV2-1, the company’s first COVID-19 oral vaccine construct that triggers mucosal immunity and includes both the S and the N SARS-Cov-2 proteins, has broad cross-coronavirus activity. The Phase I open-label study is intended to evaluate the safety and immunogenicity of Vaxart’s vaccine candidate. Data obtained from Vaxart’s oral COVID-19 vaccine Phase I trial showed substantial CD8+ T-cell responses, as measured by IFN-g and TNF-a induction. In a comparative experiment conducted by Vaxart, Phase I study data was compared to T-cell responses from volunteers subsequently vaccinated with the Moderna or Pfizer mRNA vaccine, indicating the mRNA vaccines induced fewer T-cell responses.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.
VAXART, INC. 
